Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
87446454 |
LAW OFFICE ASSIGNED |
LAW OFFICE 101 |
MARK SECTION |
MARK |
VYCEUM |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
VYCEUM |
OWNER SECTION (current) |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
OWNER SECTION (proposed) |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune
diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia,
dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and
disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases
and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders,
spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of
neurodegenerative diseases |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
11/14/2017 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/blongbottom/ |
SIGNATORY'S NAME |
Bruce W. Longbottom |
SIGNATORY'S POSITION |
Assistant General Counsel |
DATE SIGNED |
10/18/2018 |
SIGNATORY'S PHONE NUMBER |
317 651 1346 |
FILING INFORMATION |
SUBMIT DATE |
Thu Oct 18 18:07:16 EDT 2018 |
TEAS STAMP |
USPTO/ESU-XX.XXX.XXX.XX-2
0181018180716392447-87446
454-610a2962db2a42edcbcc3
b5c8091e354b812e39aba6eb7
944e2c6e7b8f8d3d68f-DA-47
95-20181018121648189824 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: VYCEUM
SERIAL NUMBER: 87446454
The applicant, Eli Lilly and Company, having an address of
Lilly Corporate Center
Indianapolis, Indiana 46285
United States
317 651 1346
317 276 1919
XXXX (authorized)
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 11/14/2017.
For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and
skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders,
diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease,
kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative
diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus
erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /blongbottom/ Date Signed: 10/18/2018
Signatory's Name: Bruce W. Longbottom
Signatory's Position: Assistant General Counsel
Signatory's Phone: 317 651 1346
RAM Sale Number: 87446454
RAM Accounting Date: 10/19/2018
Serial Number: 87446454
Internet Transmission Date: Thu Oct 18 18:07:16 EDT 2018
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XX-2018101818071639
2447-87446454-610a2962db2a42edcbcc3b5c80
91e354b812e39aba6eb7944e2c6e7b8f8d3d68f-
DA-4795-20181018121648189824